### Summary of evidence and Expert Committee recommendations

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for retinoblastoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee’s consideration of the treatment protocols for retinoblastoma is attached.